Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
WINLEVI works differently from any other topical acne treatment
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Subscribe To Our Newsletter & Stay Updated